https://www.ganaples2025.org/

Dr. Palea will be glad to meet you and discuss your R&D projects during this event.

L’article Humana in GA Naples 2025 est apparu en premier sur Humana Biosciences.

https://www.agence-adocc.com/-evenements-/btohealth-le-rendez-vous-business-et-innovation-de-la-filiere-sante-en-occitanie/

Le Dr. Palea sera disponible sur rendez-vous afin de discuter de vos projets de R&D.

L’article Humana in BtoHealth 2025 est apparu en premier sur Humana Biosciences.

Reference: J Am Soc Nephrol.2025 Feb 1;36(2):181-192.  doi: 10.1681/ASN.0000000505.
Link: https://journals.lww.com/jasn/abstract/2025/02000/a_snake_toxin_derivative_for_treatment_of.7.aspx

Humana Biosciences was charged of setting up the hyponatremia model in rats for testing the drug candidate, a peptide derivative, now in clinical development by the company V4Cure (Paris, France).

L’article A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases est apparu en premier sur Humana Biosciences.

L’article VITAFOODS 2025 in Barcelona est apparu en premier sur Humana Biosciences.

L’article Swiss Biotech Day 2025 on May 5-6 est apparu en premier sur Humana Biosciences.

Prostagutt Forte (WS® 1541) was tested using an innovative experimental model of BPH in transgenic mice where Prolactin is overexpressed in luminal prostatic cells.

We are pleased to announce the online publication on Frontiers in Pharmacology of a paper in collaboration with Dr. Vincent Goffin (Inserm, Unit 1151, Paris, France) and the Company Dr. Willmar Schwabe GmbH &Co. (Germany).

This experimental model is unique since, differently from rat models previously published, it displays several pathological features of human BPH, including:

• Marked prostate hypertrophy and hyperplasia
• Stromal infiltration of lymphocytes and macrophages
• Reduced uroflow and increased micturition frequency
• Sensitivity to various BPH treatments including 5-alpha reductase inhibitors (finasteride) and phytopharmaceuticals (Permixon® and Prostagutt®)

L’article A mouse preclinical model of Benign Prostatic Hyperplasia (BPH) useful to test drug candidates est apparu en premier sur Humana Biosciences.

In this article, he shares his vision and explains what is – sometimes – going wrong in the preclinical studies process, and how to improve it with human tissue. For instance, he explains the perks of using human tissue to study drug candidate’s efficacy and safety.

Debates have emerged since 2000s about the gap between R&D expenditures and the number of new medicines approval. Top pharmaceutical companies do not launch enough drugs to meet their growth objectives (source: 1) and for 5,000 to 10,000 compounds in the pipeline, only 1 ends up on the market (source: 2). As the cost for drug discovery and preclinical development represents around 33% of the total expenditures (source: 3) to put a new chemical entity on the market, reliable and predictive preclinical studies of fundamental importance.

Most of the failures in Phase II are due to a lack of efficacy. This fact raises the question of the translational values of preclinical tests used to select and asses the efficacy of drug candidates. A number of unanticipated differences between animal models and human could be responsible for the lack of efficacy in clinical studies.

Advantages of studying drug efficacy on human tissue:

Fresh, frozen, or formalin-fixed paraffin embedded human tissues can be used for multiple reasons:

• To confirm efficacy data obtained with recombinant cells or animal
• To identify potential side effects in vital organs that could be due to off targets activities specific to human
• To validate new targets using biomarkers
• To replace or reduce animal experimentation

Moreover, these studies could bridge the gap between in vitro cell-based studies, in vivo animal studies and clinical trials.

The use of human tissue can also be very useful to study safety as the preclinical toxicology species are not always representative of human condition. Non-clinical safety pharmacology studies performed on human tissues can be used for marketing authorization and clinical trial application, with considerable cost cuts. It also allows to replace the use of animal experimentation and above all, to provide more predictive and relevant tools to determine safety of drugs entering clinical trials.

Unfortunately, the use of human tissue in preclinical studies remains quite rare. Yet, a lot of tissue is available, but difficult to obtain because of logistic and technical difficulties, as well as the lack of incentive from surgeons or healthcare staffs, and the need for flexible working timetable for the manipulating staff.

Because of this complexity, only highly specialized, reactive and flexible CROs having years of experience in human tissue research can lead these preclinical studies.

NB : GoINPharma provides detailed and up-to-date information for professionals who wish to broaden their horizon quickly and freely. The journal is produced by a team of international professionals and is free of charge.

L’article The value of human tissue studies in translational research est apparu en premier sur Humana Biosciences.

This laboratory aims to identify, understand, predict and target cellular and molecular mechanisms responsible for the initiation, progression and/or resistance to treatment of benign and malignant tumors affecting the breast and the prostate.

This lab is specialized in translational studies that over the years have included the use and analyses of in vitro and in vivo pre-clinical models (cell lines, primary cultures, genetically-modified mouse model, tumor xenografts) and of human material (clinical samples, retrospective/prospective cohorts).

Thanks to this collaboration, Humana Biosciences has access to a validated transgenic mouse model mimicking human Benign Prostatic Hyperplasia. The complementary expertise of Humana Biosciences (unique functional urological tests) and Dr Goffin’s laboratory (histological/molecular characterization of prostates from this preclinical model^1-5) offers the opportunity of fruitful partnerships. 

Bibliography :

1— Bernichtein, S. et al. Vitamin D3 prevents calcium-induced progression of early-stage prostate tumors by counteracting TRPC6 and calcium sensing receptor upregulation. Cancer Res 77, 355-365, doi:10.1158/0008-5472.CAN-16-0687 (2017).
2— Sackmann Sala, L. et al. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumors. J Pathol 243, 54-64, doi:10.1002/path.4924 (2017).
3—Bernichtein, S. et al. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon(R)) in a mouse model of prostate hyperplasia. Prostate 75, 706-722 (2015).
4—Sackmann-Sala, L. et al. Prolactin-Induced Prostate Tumorigenesis Links Sustained Stat5 Signaling with the Amplification of Basal/Stem Cells and Emergence of Putative Luminal Progenitors. Am. J. Pathol 184, 3105-3119 (2014). 
5—Rouet, V. et al. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc Natl. Acad. Sci. U. S. A 107, 15199-15204 (2010).

L’article Partnership with Dr. Goffin est apparu en premier sur Humana Biosciences.

It supports their launch and development providing a dedicated tool answering specific needs of infrastructure. The Sicoval aims to support young biotech companies providing tools to succeed, laboratories, appropriate facilities, shared resources and economic promotion.

Prologue Biotech proposes animal facilities services, answering to Biotechs involved in preclinical assays and expertise.

Prologue Biotech is certified ISO 9001-2008, which ensure the quality and willingness to constantly improve the provided services and their consistency with the incubated companies’ needs.

To know more: http://economie.sicoval.fr/fr/creer-et-se-developper/l-appui-aux-jeunes-entreprises/pepiniere-d-entreprises-prologue-biotech.html

L’article Partnership with Sicoval est apparu en premier sur Humana Biosciences.